This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index CI
EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Advance Monday Afternoon MT
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives MT
EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer CI
Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations CI
Effector Therapeutics, Inc. Announces Director Resignations CI
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO CI
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board CI
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Health Care Down on Retreat From Risk -- Health Care Roundup DJ
Top Midday Decliners MT
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer CI
Top Premarket Decliners MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data MT
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients CI
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia CI
Chart eFFECTOR Therapeutics, Inc.
More charts
Logo eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Employees
14
More about the company
  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. News eFFECTOR Therapeutics, Inc.
  5. EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives